Tukysa Breast Cancer Therapy Boosts Progression...

By João L. Carapinha

October 15, 2025

Tukysa breast cancer therapy, developed by Pfizer, has shown remarkable efficacy in improving progression-free survival (PFS) for patients with HER2-positive metastatic breast cancer. Recent findings indicate that the combination of Tukysa (tucati...
Datroway TNBC Therapy: Transforming First-Line Treatment for Metastatic Tripl...
Lurbinectedin SCLC Therapy: FDA Approval and Its Economic Implications
Enhertu Breast Cancer Treatment: Major Advances in Invasive Disease-Free Surv...
Transforming Cancer Treatment: Implications of Subcutaneous Pembrolizumab App...
NIVOPOSTOP Trial Results: A Landmark Breakthrough in Head and Neck Cancer Tre...
NICE Kidney Cancer Guideline: Enhancing Biopsy Use to Minimize Unnecessary Su...
NICE Endorses Breakthrough Bladder Cancer Treatment for Enhanced Survival
FDA Guidance on Overall Survival Assessment in Oncology Trials
Assessment of Glofitamab With Gemcitabine in DLBCL Reveals No Additional Benefit
Most Expensive Drugs 2025: Trends and Implications in US Pharma Pricing
PADCEV KEYTRUDA Urothelial Cancer: Advancements in Survival Outcomes and Econ...
France’s HAS Denies Ribociclib Breast Cancer Therapy for Early HR+/HER2...